Candriam S.C.A. Buys New Shares in Vaxcyte, Inc. (NASDAQ:PCVX)

Candriam S.C.A. bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 114,110 shares of the company’s stock, valued at approximately $9,341,000. Candriam S.C.A. owned about 0.09% of Vaxcyte as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Whipplewood Advisors LLC acquired a new position in Vaxcyte during the fourth quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its position in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares during the last quarter. Meeder Asset Management Inc. increased its position in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares during the last quarter. Blue Trust Inc. increased its position in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. increased its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after buying an additional 775 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the sale, the chief executive officer now directly owns 136,215 shares in the company, valued at approximately $12,565,833.75. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,616 shares of company stock worth $4,768,521. Company insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Guggenheim reissued a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Stock Down 4.9 %

Shares of NASDAQ:PCVX opened at $71.18 on Friday. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The stock has a market cap of $9.17 billion, a PE ratio of -15.47 and a beta of 1.02. The business has a 50 day moving average of $83.33 and a 200-day moving average of $94.51.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. Equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.